Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: What increase in costs is justified by clinical results?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 10, 2011, Pages 345-351

  Szmurło, Daria ^a   Schubert, Agata ^b   Kostrzewska, Kaja ^a   Ryś, Przemysław ^a   Skrzekowska Baran, Iwona ^b  

^a HTA CONSULTING   (Poland)

^b Novo Nordisk Pharma Ltd   (Poland)

Author keywords

Cost effectiveness; Diabetes; Guidelines

Indexed keywords

ACARBOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CASE REPORT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES CONTROL; DISEASE COURSE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; POLAND; PRACTICE GUIDELINE; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; STROKE;

EID: 80455135026     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1089     Document Type: Article

References (26)

1. World Health Organization. Diabetes - fact sheet No 312. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. March 29, 2011.
2. [2011 Guidelines on diabetes treatment]. Diabetes Poland. Experimental and Clinical Diabetology. 2011; 11 Suppl A: A1-A48. Polish.
3. Polakowska M, Piotrowski W. Incidence of diabetes in the Polish population: results of the Multicenter Polish Population Health Status Study - WOBASZ. Pol Arch Med Wewn. 2011; 121: 156-163.
4. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 2568-2569. (Pubitemid 39281428)
5. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care. 1993; 16: 157-177. (Pubitemid 23013841)
6. Nowakowski A. [Epidemiology of diabetes]. Diabetol Prakt. 2002; 3: 181-185. Polish.
7. IDF. Annual Report 2010. http://www.idf.org/sites/default/files/Annual- Report-2010-FINAL-EN-0.pdf. March 29, 2011.
8. Chojnowski P, Wasyluk J, Grabska-Liberek I. [Diabetes - epidemiology and pathogenesis]. Post Nauk Med. 2009; 6: 420-428. Polish.
9. Wittek A, Sokalski B, Grzeszczak W, Strojek K. Prevalence of diabetes and cardiovascular risk factors of industrial area in southern Poland. Exp Clin Endocrinol Diabetes. 2009; 117: 350-353.
10. Kawalec P, Pilc A. [A cost-effectiveness analysis of treatment of diabetic complications in 2002]. Diabetol Prakt. 2004; 5: 9-14. Polish.
11. Kawalec P, Kielar M, Pilc A. [Costs related to type 1 and 2 diabetes mellitus in Poland]. Diabetol Prakt. 2006; 7: 287-294. Polish.
12. Kinalska I, Niewada M, Głogowski C, et al. [Cost of diabetes type 2 in Poland (CODIP)]. Diabetol Prakt. 2004; 5: 1-4. Polish.
13. Kissimova-Skarbek K, Pach D, Płaczkiewicz E, et al. [Evaluation of the burden of diabetes in Poland]. Pol Arch Med Wewn. 2001; 3: 867-873. Polish.
14. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004; 20 Suppl 1: S5-S26. (Pubitemid 39349905)
15. [Guidelines for Health Technology Assessment]. Agency for Health Technology Assessment. 2009. Polish. http://www.aotm.gov.pl/assets/files/ wytyczne-hta/2009/09.05.29-wytyczne-HTA-pl-MS.pdf. Accessed April 5, 2011.
16. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004; 20 Suppl 1: S27-S40. (Pubitemid 39349906)
17. Bała MM, Płaczkiewicz-Jankowska E, Topór- Ma̧dry R, et al.; ARETAEUS Study Group. Characteristics of patients with type 2 diabetes of short duration in Poland: Rationale, design and preliminary results of the ARETAEUS1 study. Pol Arch Med Wewn. 2009; 119: 533-540.
18. Bała MM, Płaczkiewicz-Jankowska E, Topór- Ma̧dry R, et al.; ARETAEUS Study Group. Is newly diagnosed type 2 diabetes treated according to the guidelines? Results of the Polish ARETAEUS1 study. Pol Arch Med Wewn. 2011; 121: 7-17.
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.
20. Szymborska-Kajanek A, Koblik T, Bandurska-Stankiewicz E, et al. [Metabolic control in type 2 diabetic patients treated by general practitioners and referred to the specialists - preliminary results of the project "The Improvement of Glycaemic Control"]. Diabetol Prakt. 2009; 10: 228-233. Polish.
21. Rutkowski B, Lichodziejewska-Niemierko M, Grenda R, et al. [Report on the renal replacement therapy in Poland - 2007]. Gdańsk 2009. Polish.
22. [Information on the contracts]. Polish National Health Fund. http://www.nfz.gov.pl/new/index.php?katnr=3&dzialnr=19&artnr=1483. Polish. Accessed April 5, 2011.
23. [74/2010/DSOZ Polish National Health Fund Directive of December 1, 2010]. http://www.nfz.gov.pl/new/index.php?katnr=3&dzialnr=12&artnr=4292. Polish. Accessed April 5, 2011.
24. [62/2009/DSOZ Polish National Health Fund Directive of November 2, 2011]. http://www.nfz.gov.pl/new/index.php?katnr=3&dzialnr=12&artnr=3901. Polish. Accessed April 5, 2011.
25. Ostrowski B. [Diabetes policy in Poland. Report of the Diabetes Poland]. Czasopismo Aptekarskie. 2008; 3: 26-34. Polish.
26. Tseng CL, Brimacombe M, Xie M, et al. Seasonal patterns in monthly hemoglobin A1c values. Am J Epidemiol. 2005; 161: 565-574. (Pubitemid 40349912)